-Estudio de Alto Riesgo de CoreValve: La FDA Determina que No se Requiere un Panel de Expertos-Baja Tasa de Mortalidad Supera las Expectativas para el Punto Final Primario-El Sistema CoreValve es la Primera y Única Válvula Aórtica Transcatéter que Presenta Resultados Superiores al Reemplazo Quirúrgico de la Válvula Aórtica MINNEAPOLIS y WASHINGTON – 29 de...
Original title: Reduction of pacemaker implantation rates alter CoreValve implantation by moderate predilatation Reference: Philipp Lange, et al. EuroIntervention 2014;9:1151-1159 Aortic valve implantation has been proven a valid strategy to treat high risk patients. The CoreValve self-expanding transcatheter aortic valve is associated with a relatively high rate of permanent pacemaker implantation and, until now, no efforts have been...
Original title: Transcatheter Aortic Valve Implantation With the Edwards SAPIEN Versus the Medtronic CoreValve Revalving System Devices. A Multicenter Collaborative Study: The PRAGMATIC Plus Initiative (Pooled-RotterdAm-Milano-Toulouse In Collaboration). Reference: Alaide Chieffo et al. J Am Coll Cardiol 2013;61:830–6. Since the introduction of percutaneous aortic valve replacement (TAVR), two devices have been widely used. For one side, the self-expanding...
Bicuspid aortic valve (BAV) disease affects 1%-2% of the population and manifests with severe aortic stenosis in the middle-aged. It characterizes for a very different anatomy with more calcification than the tricuspid aortic valve. At present, surgical aortic valve replacement (SAVR) is the first treatment indication. TAVR in this scenario has shown, in different studies,...
TAVR treatment of severe aortic stenosis is becoming more and more common, showing comparable evolution, or even superior in some studies when using the femoral approach, vs. surgical aortic valve replacement (SAVR). One of the current challenges is TAVR durability vs. SAVR. Even though 9 or 10 years has been deemed acceptable by current standards,...
Transcatheter aortic valve replacement (TAVR) has widely demonstrated its significant benefits, both in high-risk and inoperable patients, as well as in those with intermediate and low risk. While paravalvular regurgitation has been a challenge, its management has improved with operator experience and a deeper understanding of CT angiographies. However, in cases of regurgitation, elevated gradient,...
In recent years, there has been a steady increase in the use of transcatheter aortic valve replacement (TAVR) in younger patients, with an average age of 74 years, as observed in US medical records. This trend goes alongside encouraging durability results, as demonstrated in the 10-year NOTION study, where structural valve degeneration (SVD) with first-generation...
Prosthesis-patient mismatch (PPM) occurs when the effective orifice area (EOA) after valve placement is significantly smaller compared with the patient’s body surface area (BSA), resulting in an increased transprosthetic residual gradient. The presence of PPM, especially in various surgical series, has been associated with long-term adverse clinical events. In relation to transcatheter aortic valve implantation...
In Europe and the US, aortic stenosis is the most frequent cause of valve intervention, both surgical and percutaneous, and, as we all know, TAVR has made great progress in this regard. However, this technique has an Achilles heel when it comes to self-expandable valves: definite pacemaker implantation rate is 3 to 4 times higher...
This last year, new data in structural heart disease gave way to changes in practices and new hypotheses, when not simply further justified the already existing evidence. In this new editorial section, we share the most relevant of last year’s works to keep you up to speed on the main topics in the field. The...